Dechra Pharmaceuticals (DPH)

 

DPH Share PerformanceMore

52 week high1,900.0 26/05/17
52 week low811.0 24/06/16
52 week change 701.0 (60.02%)
4 week volume3,240,450 02/05/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 5577F Dechra Pharmaceuticals PLC 18 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii DECHRA PHARMACEUTICALS PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal o...

Director/PDMR Shareholding

RNS Number: 1053E Dechra Pharmaceuticals PLC 03 May 2017 3 May 2017 Dechra Pharmaceuticals PLC (Dechra or the Company) In accordance with article 19(1) of the Market Abuse Regulations, the Company announces that on 2 May 2017 Ian Page exercised options under the Company's Save As Year Earn Option Scheme over 1,630 ordinary shares each at an opt...

Total Voting Rights

RNS Number: 7342D Dechra Pharmaceuticals PLC 28 April 2017 28 April 2017 Dechra Pharmaceuticals PLC (Dechra or the Company) Total Voting Rights In conformity with DTR 5.6.1R, the Company notifies the market of the following: As at the date of this announcement, the Company's issued share capital consists of 93,104,111 ordinary shares with a nominal valu...

Director Deals - Dechra Pharmaceuticals PLC (DPH)

Ian Page, Chief Executive Officer, has transferred out 6,600 shares in the company on the 24th April 2017 at a price of 0.00...

Director/PDMR Shareholding

RNS Number: 1418D Dechra Pharmaceuticals PLC 24 April 2017 24 April 2017 Dechra Pharmaceuticals PLC (Dechra or the Company) In accordance with article 19(1) of the Market Abuse Regulations, the Company was notified today that due to a change in personal circumstances Ian Page's total beneficial interest in the Company is now 811,308 shares, which represen...

Holding(s) in Company

RNS Number: 0217D Dechra Pharmaceuticals PLC 21 April 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii DECHRA PHARMACEUTICALS PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal...

Additional Listing

RNS Number: 2063C Dechra Pharmaceuticals PLC 11 April 2017 11 April 2017 Dechra Pharmaceuticals PLC (Dechra or the Company) Additional Listing An application has been made to the Financial Conduct Authority and the London Stock Exchange for a total of 75,000 ordinary shares of 1 pence each (the "Shares") to be admitted to the Official List. These Shares ...

Broker Forecast - Numis issues a broker note on Dechra Pharmaceuticals PLC

Numis today reaffirms its add investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target t...

Fundamental DataMore

P/E ratio133.5
EPS14
Dividend yield0.988 %

Equity Research (DPH)

edison investment research
Dechra Pharmaceuticals plc
10/09/2015
Dechra Pharmaceuticals delivered FY15 revenue growth of 10% CER to £203.5m and EPS growth of 16.9% from 36.3p to 39.9p, with strong sales performances in its Companion Animal Products (CAP) segment,...
edison investment research
Dechra Pharmaceuticals plc
08/07/2015
Dechra Pharmaceuticals’ medium-term outlook is underpinned by a sharpened portfolio focus, new product launches and geographic expansion. Solid performances on these fronts in FY15 have overcome the...
edison investment research
Dechra Pharmaceuticals plc
29/04/2015
Dechra Pharmaceuticals has delivered another solid quarter with revenue growth up 6.0% (14.3% CER), resulting in nine-month growth of 6.6% (12.3% CER). Although boosted by phasing of pre-Easter...

Latest discussion posts More

  • Re: Overvalued?

    Hi Pharma Do you have a reference / weblink for the future earnings forecasts? I only ask as I've had a look through the recent results and last year's annual report and ...
    17-May-2017
    robmonster
  • Re: Overvalued?

    In actual fact the p/e of Dechra seems so high because it is based on the most recent annual earnings. If you base it on next years earnings it comes down to just under 30 and ...
    16-May-2017
    pharmaspecialist
  • Re: Overvalued?

    Valeite, "Lloyds have been added to the CF Woodford Income fund" That fact alone should be enough to warn one off Lloyds LOL. I shall stick with Dechra notwithstanding ...
    16-May-2017
    LK Hyman

Users' HoldingsMore

Users who hold Dechra Pharmaceuticals also hold..
NATIONAL GRID42%
DIAGEO37%
LLOYDS GRP.30%
SHIRE25%
PZ CUSSONS24%

Codes & Symbols

ISINGB0009633180
SymbolsDPH, LSE:DPH, DPH.L, DPH:LN, LON:DPH, XLON:DPH